- Home
- AEVA vs TLSI Comparison
AEVA vs TLSI Comparison
Compare AEVA & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEVA
- TLSI
- Stock Information
- Founded
- AEVA 2019
- TLSI 2010
- Country
- AEVA United States
- TLSI United States
- Employees
- AEVA N/A
- TLSI N/A
- Industry
- AEVA Auto Parts:O.E.M.
- TLSI Medical Specialities
- Sector
- AEVA Consumer Discretionary
- TLSI Health Care
- Exchange
- AEVA Nasdaq
- TLSI Nasdaq
- Market Cap
- AEVA 177.0M
- TLSI 166.8M
- IPO Year
- AEVA N/A
- TLSI N/A
- Fundamental
- Price
- AEVA $2.44
- TLSI $5.00
- Analyst Decision
- AEVA Buy
- TLSI Strong Buy
- Analyst Count
- AEVA 5
- TLSI 2
- Target Price
- AEVA $10.03
- TLSI $14.00
- AVG Volume (30 Days)
- AEVA 273.5K
- TLSI 64.0K
- Earning Date
- AEVA 08-07-2024
- TLSI 08-14-2024
- Dividend Yield
- AEVA N/A
- TLSI N/A
- EPS Growth
- AEVA N/A
- TLSI N/A
- EPS
- AEVA N/A
- TLSI N/A
- Revenue
- AEVA $6,540,000.00
- TLSI $24,736,000.00
- Revenue This Year
- AEVA $109.97
- TLSI $61.24
- Revenue Next Year
- AEVA $136.96
- TLSI $47.32
- P/E Ratio
- AEVA N/A
- TLSI N/A
- Revenue Growth
- AEVA 89.40
- TLSI 67.75
- 52 Week Low
- AEVA $2.20
- TLSI $3.32
- 52 Week High
- AEVA $7.25
- TLSI $10.42
- Technical
- Relative Strength Index (RSI)
- AEVA 35.73
- TLSI 38.30
- Support Level
- AEVA $2.79
- TLSI $4.80
- Resistance Level
- AEVA $3.11
- TLSI $5.47
- Average True Range (ATR)
- AEVA 0.24
- TLSI 0.35
- MACD
- AEVA -0.06
- TLSI -0.05
- Stochastic Oscillator
- AEVA 8.08
- TLSI 16.82
About AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.